Roche

News

After phase 3 clean sweep, Roche plans oral BTK filing in MS

Roche is preparing to file for its oral multiple sclerosis drug fenebrutinib after a third phase 3 win, but could liver toxicity be a stumbling block?

News

Mark Dawson named head of Roche's pRED unit

Roche has appointed leading Australian cancer researcher Mark Dawson to lead its pRED R&D division, as the company prepares for a steep patent cliff.

News

Roche trial offers hope to patients with rare kidney disease

A study of Roche's Gazyva has raised the prospect of a first approved therapy for the rare kidney disorder primary membranous nephropathy.

News

Data builds on Roche's dominance in primary progressive MS

Roche looks on track to add oral BTK inhibitor fenebrutinib to treatment options for primary progressive multiple sclerosis.

News

CMS's Medicare price negotiations start round three

The US federal government has named the next 15 big-selling medicines that will be subject to Medicare pricing negotiations.

News

Roche claims midstage win for obesity injectable

Roche reports weight loss of up to 22.5% with its injectable GIP/GLP-1 agonist obesity drug, setting up phase 3, but will it be too late to the table?

After phase 3 clean sweep, Roche plans oral BTK filing in MS

Mark Dawson named head of Roche's pRED unit

Roche trial offers hope to patients with rare kidney disease

Data builds on Roche's dominance in primary progressive MS

CMS's Medicare price negotiations start round three

Roche claims midstage win for obesity injectable

Bayer gets swift review for Kerendia in type 1 diabetes

Discover a new era of healthcare panel engagement: Grounded ...

Roche

Editor's Picks